Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Mineralys Therapeutics (MLYS) is trading at $23.30, down 1.40% on the day. Its market value of $2.06B makes it the 2754th largest of the 3132 companies we follow.
It is close to the bottom of its 52-week range ($22.30 to $47.65), 51.1% under the high. Holders are behind 38.7% over twelve months, and down 23.5% across the last three months.
On the chart it has slipped under both the 50-day ($26.79) and 200-day ($28.36) moving averages; RSI is 34, and the last 30 sessions moved at roughly 67% annualized volatility.
Revenue for ANNUAL, ended Dec 2025 was $0.00, and a net loss of $154.65M.
6 analysts follow the stock and the average call is "buy". The mean target, $51.00, sits 118.9% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 2 factors below, ranked against the 3132 U.S. stocks BeStock covers.
Trading closer to its 52-week high than most peers scores higher.
6 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
MLYS is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $51.00, 118.9% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $21.79, so shares trade 6.9% above that estimate.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -14.3% | Bearish |
| Price vs 50-day average | -13.0% | Bearish |
| Price vs 200-day average | -17.8% | Bearish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 34.0 | Bearish |
| MACD (12,26,9) | -0.95 | Bearish |
| Bollinger band position | 8% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 5, 2026 10:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$23.30 is the latest print for MLYS, a move of -1.40% against yesterday's close of $23.63. Today's low and high so far: $22.97 and $24.00.
Equity value comes to $2.06B at the current price. By that measure it is number 2754 of the 3132 names in our coverage.
The year's floor is $22.30 and the ceiling $47.65. Shares are 51.1% away from that ceiling.
Our data shows no dividend paid by Mineralys Therapeutics over the trailing twelve months.
Of 6 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $51.00, with the most cautious at $40.00 and the most optimistic at $56.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on MLYS.